A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma

References

• Vose J M, Anderson J R, Kessinger A, Bierman E J, Coccia P, Reed E C, et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846–1151
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Hagemeister F B, Romaguera J E, Sarris A H, Pate O, Younes A. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14: 1262–1268
   PubMed Web of Science ®Google Scholar
• Johnson P WM, Rohatiner Z S, Whelan J S, Price C GA, Love S, Lim J, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13: 140–147
   PubMed Web of Science ®Google Scholar
• Hass R, Moos M, Karcher A, Mohle R, Witt B, Goldschmidt H, et al. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 1685–1692
   PubMed Web of Science ®Google Scholar
• Smith M L, Newland A C. Treatment of myeloma. Q J Med 1999; 92: 11–14
   Google Scholar
• Balzarini J, Wedgwood O, Kruining S, Pelemans H, Heijtink R, De Clercq E, et al. Anti-HIV and anti-HBV activity and resistance profile of 2′,3′-dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochem Biophys Res Commun 1996; 225: 363–369
   PubMed Web of Science ®Google Scholar
• Mar E C, Chu C J, Lin J C. Some nucleoside analogs with anti-human immunodeficiency virus activity inhibit replication of Epstein-Barr virus. Antiviral Res 1995; 28: 1–11
   PubMed Web of Science ®Google Scholar
• Coates J A, Cammack N, Jenkinson H J, Jowett A J, Mowett M I, Pearson B A, et al. (–)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 1992; 36: 733–739
   PubMed Web of Science ®Google Scholar
• Mansour T S, Jin H, Wang W, Hooke E U, Ashman C, Cammack N, et al. Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2′-deoxy-3′-oxa-4′-thiocytidine and their 5-fluoro analogues in vitro. J Med Chem 1995; 38: 1–4
   PubMed Web of Science ®Google Scholar
• Grove K L, Cheng Y C. Uptake and metabolism of the new anticancer compound beta-L-(–)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res 1996; 56: 4187–4191
   PubMed Web of Science ®Google Scholar
• Grove K L, Guo X, Liu S H, Gao Z, Chu C K, Chen Y C. Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res 1995; 55: 3008–3011
   PubMed Web of Science ®Google Scholar
• Kadhim S A, Bowlin T L, Waud W R, Angers E G, Bibeau L, DeMuys J M, et al. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res 1997; 57: 4803–4810
   PubMed Web of Science ®Google Scholar
• Siu L L, Attardo G, Izbicka E, Lawrence R, Cerna C, Gomez L, et al. Activity of (–)-2′-deoxy-3′-oxacytidine (BCH-4556) against human tumor colony-forming units. Ann Oncol 1998; 9: 885–891
   PubMed Web of Science ®Google Scholar
• Giles F J, Cortes J E, Baker S D, Thomas D A, O'Brien S, Smith T L, et al. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol 2001; 19: 762–771
   PubMed Web of Science ®Google Scholar
• Oken M M, Creech R T, Tormey D C, Horton J, Davis T E, McFadden E T, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655
   PubMed Web of Science ®Google Scholar
• Cockcroft D W, Gault M H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp V A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Rai K R, Grever H R, Kay N E, Schiffer C a, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 1988; 29: 152–163
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Kukhanova M, Liu S, Mozzherin D, Lin T, Chu C K, Cheng Y. L- and D-enantiomers of 2′,3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases Implications for the mechanism of toxicity. J Biol Chem 1995; 270: 23055–23059
   PubMed Web of Science ®Google Scholar
• Chou K K, Kukhanova M, Cheng Y. A novel action of human apurinic/apyrimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3′ termini of DNA. J Biol Chem 2000; 275: 31009–31015
   PubMed Web of Science ®Google Scholar
• Gourdeau H, Leblond L, Hamelin B, Dong K, Quellet F, Boudreau C, et al. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development. Clin Cancer Res 2004; 10: 7692–7702
   PubMed Web of Science ®Google Scholar
• Giles F J, Faderl S, Thomas D A, Cortes J B, Garcia-Manero G, et al. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol 2003; 21: 1050–1056
   PubMed Web of Science ®Google Scholar